RBS PLC LAUNCHES THE RBS GLOBAL BIG PHARMA EXCHANGE TRADED NOTES (DRGS)
RBS Securities Inc. (RBSSI) today announced the launch of the fifth exchange traded product in its growing suite of Exchange Traded Notes (ETNs). The RBS Global Big Pharma Exchange Traded Notes will be issued by The Royal Bank of Scotland plc (RBS plc) and will be listed on NYSE Arca, Inc. under the ticker (NYSE:DRGS).
The ETNs are designed for investors who seek exposure to the NYSE Arca Equal Weighted Pharmaceutical Total Return Index, an index that is designed to track the performance of the equity securities of a cross-section of global companies involved in various phases of the development, production and marketing of pharmaceuticals. The Index currently comprises stocks and depositary receipts of 16 large cap global pharmaceutical companies.
Payment on the ETNs is linked to the performance of the Index, less an investor fee that is deducted daily at an annualized rate of 0.60%. Investors have the right to require RBS plc to repurchase the ETNs on a daily basis, subject to a minimum repurchase requirement. RBS plc, at its sole discretion, may also redeem the ETNs at any time prior to maturity.
“The RBS Global Big Pharma ETNs are designed for investors who seek an equally weighted pure play on the global pharmaceutical industry,” said Michael Nelskyla, Head of Structured Retail Distribution, Americas.
The final pricing supplement can be found on the SEC website: HERE
The Royal Bank of Scotland plc: